AC Immune Shares Surge on Positive Phase 2 Parkinson’s Data and $100M Takeda Deal
By ATTN Desk · Editorial oversight: Sean Han
Introduction
AC IMMUNE SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicine approaches for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and rare “NeuroOrphan” indications driven by misfolded proteins. Its proprietary platforms—SupraAntigen® and Morphomer®—support a diversified pipeline of active immunotherapies, antibodies, small molecules, and diagnostics.
Corporate Structure
With headquarters in Lausanne and regional operations in North America, AC Immune employs between 51 and 200 staff. The senior leadership team includes CEO Dr. Andrea Pfeifer and CFO Christopher Roberts. The company has collaborations with Janssen Pharmaceuticals, Takeda, and Eli Lilly, which assist in advancing multiple clinical- and preclinical-stage assets.
Immunotherapy by Alex Robertson
Recent Developments
- May 13, 2024: AC Immune and Takeda signed an exclusive option and license agreement for ACI-24.060, an active immunotherapy targeting toxic forms of amyloid-beta. AC Immune received a $100 million upfront payment and may earn up to $2.1 billion in milestones plus tiered double-digit royalties upon commercialization.
- September 4, 2025: The company announced a 30 percent workforce reduction to streamline operations focused on three clinical-stage active immunotherapies, two pharmaceutical collaborations, and small-molecule programs targeting NLRP3 and Tau. Management indicated this measure is aimed at extending the cash runway through Q3 2027.
- December 9, 2025: Shares of ACIU closed at $3.49 on the Nasdaq Global Market, a 25.09 percent increase from the prior close, with a trading volume of 3,607,790 shares. The stock’s 52-week range is $1.43 to $4.00.
- December 11, 2025: AC Immune reported interim safety and efficacy data from the Phase 2 VacSYn trial of ACI-7104.056 in early Parkinson’s disease, indicating that active immunotherapy targeting alpha-synuclein pathology may influence disease progression.
Financial and Strategic Analysis
AC Immune’s market capitalization is approximately $255.5 million, with an enterprise value of $126.8 million. Trailing twelve-month revenue is reported at $4.37 million against a net loss of $71.87 million. The company holds $108.47 million in cash and cash equivalents, with a debt/equity ratio of 7.46 percent. Key valuation metrics include a price/sales ratio of 47.09 and price/book of 3.30.
Strategically, AC Immune seeks to balance internal pipeline investment with external partnerships to manage development risk and conserve capital. The at-the-market offering of up to $80 million and milestone payments from Takeda support its funding model. By focusing on key candidates in Alzheimer’s and Parkinson’s diseases and extending cash through Q3 2027, management aims to facilitate important value-inflection events without immediate equity dilution.
| Metric | Value |
|---|---|
| Market Capitalization | $255.5 million |
| Enterprise Value | $126.8 million |
| Revenue (TTM) | $4.37 million |
| Net Income (TTM) | –$71.87 million |
| Cash & Cash Equivalents (MRQ) | $108.47 million |
| Debt/Equity (MRQ) | 7.46 percent |
| Price/Sales (TTM) | 47.09 |
| Price/Book (MRQ) | 3.30 |
Market Position and Industry Context
AC Immune focuses on precision prevention for neurodegenerative disorders, a therapeutic area with increasing unmet needs as global aging trends progress. Its SupraAntigen and Morphomer platforms address underlying protein misfolding, setting the company apart from those developing solely monoclonal antibodies or small molecules. Collaborations with larger pharmaceutical firms validate its scientific approach and enhance funding opportunities. Competitive pressures exist from other biotech companies and established pharmaceutical groups pursuing anti-amyloid and anti-tau therapies, as well as emerging gene-therapy and cell-therapy modalities.
TL;DR
- On December 11, 2025, AC Immune reported interim data from its Phase 2 VacSYn trial of ACI-7104.056 in early Parkinson’s disease.
- Shares increased 25.09 percent to $3.49 on December 9, influenced by the trial update and a cash runway extending through Q3 2027.
- Strategic collaborations (Takeda option for ACI-24.060) and a workforce reduction of 30 percent support funding without immediate equity raises.
- The company holds $108 million in cash, a market cap of $255.5 million, and concentrates on immunotherapies for Alzheimer’s and Parkinson’s diseases.